Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 310

  • Showing results for paolo casali. Search instead for Paolo Castaldi (1 item)
1.

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.

Gronchi A, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY, Casali PG.

JAMA Surg. 2020 Apr 1:e200397. doi: 10.1001/jamasurg.2020.0397. [Epub ahead of print]

PMID:
32236507
2.

Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU).

Casali PG, Trama A.

ESMO Open. 2020 Mar;5(2). pii: e000666. doi: 10.1136/esmoopen-2019-000666.

3.

Current models, challenges and best practices for work conducted between European academic cooperative groups and industry.

Stahel RA, Lacombe D, Cardoso F, Casali PG, Negrouk A, Marais R, Hiltbrunner A, Vyas M; Clinical Academic Cancer Research Forum (CAREFOR).

ESMO Open. 2020 Mar;5(2). pii: e000628. doi: 10.1136/esmoopen-2019-000628.

4.

Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M.

Clin Cancer Res. 2020 Mar 1;26(5):1199. doi: 10.1158/1078-0432.CCR-20-0172. No abstract available.

PMID:
32122930
5.

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Cruz J, Penel N, Le Cesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, Lopez-Guerrero JA, Dopazo J, Peña-Chilet M, Gutierrez A, Collini P, Karanian M, Redondo A, Lopez-Pousa A, Grignani G, Diaz-Martin J, Marcilla D, Fernandez-Serra A, Gonzalez-Aguilera C, Casali PG, Blay JY, Stacchiotti S.

Lancet Oncol. 2020 Mar;21(3):456-466. doi: 10.1016/S1470-2045(19)30826-5. Epub 2020 Feb 14.

PMID:
32066540
6.

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, Casali PG, Pilotti S, D'Incalci M, Frapolli R.

Br J Cancer. 2020 Mar;122(7):1120. doi: 10.1038/s41416-020-0746-5.

7.

The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.

Desmoid Tumor Working Group.

Eur J Cancer. 2020 Mar;127:96-107. doi: 10.1016/j.ejca.2019.11.013. Epub 2020 Jan 28. Review.

8.

B Cell Endosomal RAB7 Promotes TRAF6 K63 Polyubiquitination and NF-κB Activation for Antibody Class-Switching.

Yan H, Fernandez M, Wang J, Wu S, Wang R, Lou Z, Moroney JB, Rivera CE, Taylor JR, Gan H, Zan H, Kolvaskyy D, Liu D, Casali P, Xu Z.

J Immunol. 2020 Mar 1;204(5):1146-1157. doi: 10.4049/jimmunol.1901170. Epub 2020 Jan 13.

PMID:
31932498
9.

B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids.

Sanchez HN, Moroney JB, Gan H, Shen T, Im JL, Li T, Taylor JR, Zan H, Casali P.

Nat Commun. 2020 Jan 2;11(1):60. doi: 10.1038/s41467-019-13603-6.

10.

Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.

Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VVM, Levy A, Griffin AM, Hayes AJ, Stacchiotti S, Pèchoux CL, Smith MJ, Fiore M, Tos APD, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MAJ, Casali PG, Wunder JS, Gronchi A.

EClinicalMedicine. 2019 Nov 22;17:100215. doi: 10.1016/j.eclinm.2019.11.008. eCollection 2019 Dec.

11.

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S.

Cancer. 2020 Jan 1;126(1):98-104. doi: 10.1002/cncr.32508. Epub 2019 Sep 19.

PMID:
31536651
12.

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M.

Clin Cancer Res. 2019 Dec 15;25(24):7565-7575. doi: 10.1158/1078-0432.CCR-19-0976. Epub 2019 Sep 3. Erratum in: Clin Cancer Res. 2020 Mar 1;26(5):1199.

PMID:
31481505
13.

Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.

Hohenberger P, Bonvalot S, van Coevorden F, Rutkowski P, Stoeckle E, Olungu C, Litiere S, Wardelmann E, Gronchi A, Casali P.

Eur J Cancer. 2019 Oct;120:47-53. doi: 10.1016/j.ejca.2019.07.028. Epub 2019 Aug 31.

PMID:
31479947
14.

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, Casali PG, Pilotti S, D'Incalci M, Frapolli R.

Br J Cancer. 2019 Sep;121(6):464-473. doi: 10.1038/s41416-019-0550-2. Epub 2019 Aug 14. Erratum in: Br J Cancer. 2020 Feb 11;:.

PMID:
31409911
15.

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.

Lancet Oncol. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5. Epub 2019 Jul 19. Erratum in: Lancet Oncol. 2019 Oct;20(10):e559.

PMID:
31331701
16.

Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.

Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N.

Cancers (Basel). 2019 Jul 19;11(7). pii: E1015. doi: 10.3390/cancers11071015.

17.

Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis.

Nizri E, Fiore M, Barretta F, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Stacchiotti S, Casali PG, Miceli R, Gronchi A.

Ann Surg Oncol. 2019 Oct;26(11):3535-3541. doi: 10.1245/s10434-019-07615-1. Epub 2019 Jul 16.

PMID:
31313035
18.

Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).

Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG.

Clin Cancer Res. 2019 Sep 1;25(17):5295-5300. doi: 10.1158/1078-0432.CCR-19-0288. Epub 2019 Jun 19.

PMID:
31217199
19.

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.

Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J.

EClinicalMedicine. 2019 Mar 11;9:35-43. doi: 10.1016/j.eclinm.2019.03.007. eCollection 2019 Mar.

20.

Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors.

Tirotta F, Fumagalli E, Colombo C, Morosi C, Barisella M, Radaelli S, Frezza AM, Casali PG, Gronchi A, Fiore M.

J Surg Oncol. 2019 Aug;120(2):256-261. doi: 10.1002/jso.25491. Epub 2019 May 7.

PMID:
31066052

Supplemental Content

Loading ...
Support Center